Olga A. Martin

Olga A. Martin

Auto-generated profile, based on publicly available information

Olga A. Martin

Centre of Medical Radiation Physics (CMRP), University of Wollongong, Wollongong, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Communicative & Integrative Biology
Verified
Journal Article
Open access
OMOlga A. Martin
Olga A. Martin
CRChristophe Redon
Christophe Redon
JDJennifer S. Dickey
Jennifer S. Dickey
ANAsako J. Nakamura
Asako J. Nakamura
WBWilliam M. Bonner
William M. Bonner
The radiation induced bystander effect is a well accepted consequence of ionizing radiation exposure. However, it has become clear that bystander responses in vitro can result from a number of stress stimuli. We had reported that media conditioned on tumor cell cultures induced a bystander effect in recipient normal cell cultures and asked whether an analogous process could occur in vivo - could the presence of a tumor induce DNA damage in distant tissues. We recently demonstrated the presence of a distant bystander DNA damage response in vivo in the gastrointestinal organs and skin of mice implanted with subcutaneous tumors. The activation of inflammatory macrophages through the cytokine CCL2 was found to be required for this distant genotoxic response. These results shed new light on the consequences of tumor growth to distant parts of the body and highlight the potential for possible medical interventions to mitigate the effect of cancers.

1 January 2011 in Communicative & Integrative Biology
Verified
Journal Article
Closed access
OMOlga A Martin
Olga A Martin
CRChristophe Redon
Christophe Redon
JDJennifer S Dickey
Jennifer S Dickey
ANAsako J. Nakamura
Asako J. Nakamura
WBWilliam M Bonner
William M Bonner
The radiation induced bystander effect is a well-accepted consequence of ionizing radiation exposure. However, it has become clear that bystander responses in vitro can result from a number of stress stimuli. We had reported that media conditioned on tumor cell cultures induced a bystander effect in recipient normal cell cultures and asked whether an analogous process could occur in vivo-could the presence of a tumor induce DNA damage in distant tissues. We recently demonstrated the presence of a distant bystander DNA damage response in vivo in the gastrointestinal organs and skin of mice implanted with subcutaneous tumors. The activation of inflammatory macrophages through the cytokine CCL2 was found to be required for this distant genotoxic response. These results shed new light on the consequences of tumor growth to distant parts of the body and highlight the potential for possible medical interventions to mitigate the effect of cancers.

14 November 2024 in Cancer Letters
Verified
Journal Article
Open access
VTVerdiana Trappetti
Verdiana Trappetti
Cristian Fernandez-PalomoCristian Fernandez-Palomo
Cristian Fernandez-Palomo
PAPrateek Arora
Prateek Arora
MPMarine Potez
Marine Potez
PPPaolo Pellicioli
Paolo Pellicioli
Valentin DjonovValentin Djonov
Valentin Djonov
Despite the recent progress, current treatment modalities are not able to eradicate cancer. We show that Microbeam Radiotherapy (MRT), an innovative type of Spatially Fractionated Radiotherapy, can control murine melanoma by activating the host's own immune system. The beneficial effects are very pronounced in comparison to uniform radiotherapy traditionally employed in the clinic. Our results show that MRT increased antigen presentation, activating Cytotoxic T Lymphocytes (CTLs) which are essential to MRT's treatment efficacy in melanoma. Depletion of CTLs abrogated treatment response. Multiplex nucleic acid hybridization technology revealed key features of lymphocyte populations such as proliferation, differentiation, and ligand-receptor interactions. In addition, CTLs were shown to be essential for locoregional metastatic control and systemic abscopal effects confirmed by activation of antigen presenting cells and CTL trafficking in the tumour-draining lymph nodes. MRT also showed a synergistic effect with immunotherapy. Overall, MRT induces a robust antitumour immune response, acting like an in situ vaccination, which could be exploited to treat a variety of treatment-resistant malignancies.

1 July 2018 in Cancer Research
Verified
Journal Article
Closed access
JVJessica Ventura
Jessica Ventura
PLPavel Lobachevsky
Pavel Lobachevsky
JPJason Palazzolo
Jason Palazzolo
HFHelen Forrester
Helen Forrester
NHNicole Haynes
Nicole Haynes
OMOlga A. Martin
Olga A. Martin
The discovery of the radiation-induced bystander effect has expanded knowledge of radiobiological mechanisms of ionizing radiation. A counterpart in vivo phenomenon is the radiation-induced abscopal effect (RIAE). It is not known how radiation settings affect non-targeted normal tissues and therefore the risk of adverse RIAE. At the Australian Synchrotron we examined systemic effects of microbeam radiotherapy (MRT) and broad beam (BB) configurations, in mice that were locally exposed to a very short pulse of a high dose-rate synchrotron beam (49 Gy/sec). We determined how radiation volume and dose impact the RIAE. C57BL/6 mice were irradiated with 10 or 40 Gy incident dose of MRT or BB in an 8x8, 8x1, or 2x2-mm area of the right hind leg. Blood samples, irradiated skin and a variety of normal unirradiated tissues were collected for DNA damage analysis of double-strand breaks (DSBs) quantified as gamma-H2AX foci and oxidatitive clustered DNA lesions (OCDL). OCDLs elevated in a wide variety of unirradiated normal tissues. In out-of-field duodenum, a trend for elevated apoptotic cells was observed, however DSBs elevated only after exposure to lower doses. These genotoxic events were accompanied by changes in concentrations of MDC, CCL2/MCP1, Eotaxin, IL-10, TIMP-1, VEGF, TGFβ-1 and TGFβ-2 plasma cytokines and by changes in frequencies of macrophages, neutrophils and T-lymphocytes in duodenum. Overall, systemic radiation responses were dose-independent (1). The MRT irradiations was repeated in immune-deficient mice: NSG, CCL2 knock-outs, and in C57BL/6 mice treated with anti-CSF1R antibody which effectively depletes macrophages. Strikingly, these effects and the abscopal innate and adaptive immune effector responses were completely or partially abrogated in the mice with various immune deficiencies, highlighting the role of the functional immune system in propagation of systemic genotoxic effects of radiation. These findings have implications for the planning of therapeutic and diagnostic radiation to reduce the risk of radiation-related adverse systemic effects. 1. Ventura et al, Cancer Research, e-pub (2017). Citation Format: Jessica Ventura, Pavel Lobachevsky, Jason Palazzolo, Helen Forrester, Nicole Haynes, Alesia Ivashkevich, Andrew Stevenson, Christopher Hall, Vassilis Gorgoulis, John Hamilton, Alexandros Georgakilas, Calr Sprung, Olga A. Martin. Localized synchrotron radiation in mice induces persistent systemic genotoxic events mediated by the functional immune system [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4573.

13 November 2024 in Advances in Radiation Oncology
Verified
Journal Article
Open access
EEElette Engels
Elette Engels
HFHelen Forrester
Helen Forrester
MKMitzi Klein
Mitzi Klein
CBCaroline Bell
Caroline Bell
IBIndi Balderstone
Indi Balderstone
OMOlga A. Martin
Olga A. Martin
Both local tumor control and distant metastasis are important indicators of the efficacy of radiation therapy treatment. Synchrotron microbeam radiation therapy (MRT), spatially fractionated radiation delivered at ultrahigh dose rates, shows remarkable normal tissue sparing with excellent local control in some models. Some MRT regimens trigger an antitumor immune response that contributes not only to the local but also to systemic treatment efficacy. Despite recent advances in the treatment of primary breast cancer, metastatic disease is still the major cause of treatment failure in the clinic. Here, in an aggressive preclinical triple-negative breast cancer model, we compared local tumor response and metastasis following different MRT treatment programs. 4T1.2 mouse mammary tumors were treated with 300 Gy peak/7 Gy valley dose MRT and/or 8 Gy broad beam (BB) radiation, all delivered as daily fractionated programs (3 consecutive daily sessions of either MRT or BB or 1 MRT combined with 2 BB sessions, the first or last of the 3 fractions). The mice were euthanized on day 9 post last irradiation, when unirradiated control animals reached an ethical endpoint. Primary tumors were collected to evaluate immune cell prevalence, while lungs, spinal cords, and locoregional lymph nodes were collected to measure metastatic burden. In parallel, local tumor growth and survival were monitored. The combined MRT/BB treatment shifted the balance between pro- and antitumorigenic macrophages toward the accumulation of antitumorigenic macrophages in the tumor. Monitoring of the tumor volume and animal health indicated the benefit of the combined MRT/BB treatment for local control and treatment tolerance, while animal survival was only marginally longer for one combined schedule. The metastatic burden was similar for all 4 treatment schedules. The addition of a single MRT to BB treatment improved the primary tumor response. This provides a basis for future experiments incorporating adjuvant immunotherapy or chemotherapy to improve local and systemic treatment outcomes.

8 November 2025 in Advances in Radiation Oncology
Verified
Journal Article
Open access
EEElette Engels
Elette Engels
HFHelen B. Forrester
Helen B. Forrester
VTVerdiana Trappetti
Verdiana Trappetti
KMKellie Mouchemore
Kellie Mouchemore
MKMitzi Klein
Mitzi Klein
VDValentin G. Djonov
Valentin G. Djonov
The superior therapeutic index of preclinical synchrotron microbeam radiation therapy (MRT) over conventional broad-beam (BB) radiation therapy (RT) has been clearly established. Published data demonstrate that a combination of 1 MRT session with 2 consecutive daily BB-RT sessions effectively controls the primary tumor and triggers an antitumor immune response. Here, we aimed to establish whether an ultrahigh dose rate of MRT, available exclusively on the synchrotron, is essential for effective treatment of murine triple-negative mammary carcinoma. The in vitro response of mammary tumor cells was investigated using a clonogenic survival assay at different MRT dose rates (∼1000, 100, or 10 Gy/s). The in vivo tumor responses at the same dose rates, with an MRT/BB/BB treatment schedule, were evaluated by measuring tumor volume and the induced immune response. Animal survival and normal skin reactions were also assessed. Clonogenic survival decreased with decreasing MRT dose rate, with most cell sparing at the highest dose rate (1000 Gy/s), indicating that lower dose rates could be more effective against tumors. However, no significant differences in in vivo tumor growth delay were observed in response to dose-rate variations. Decreased infiltration of irradiated tumors with leucocytes and their subpopulations was observed at the lower dose rates, including decreased expression of immune checkpoints PD-1/PD-L1 and prognostic marker CD103, which could impact the overall tumor response in vivo. The higher dose rates were associated with increased antitumor immunity. Early euthanasia of mice, as dictated by ethical endpoints, prevented long-term observation of differences in animal survival. Skin toxicity in the vicinity of irradiated tumors was mild and developed later at the highest MRT dose rate. Overall, MRT at 10 to 1000 Gy/s was tolerated similarly, despite dramatic changes in the dose rate. These findings are promising for the clinical translation of MRT in combination with conventional RT, using emerging compact x-ray MRT sources with dose rates lower than those delivered by synchrotron sources.